Clinical Trials · NCT06409130
Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 270
- Start date
- May 2024
- Locations
- 102 sites, 14 countries
- Primary endpoint
- Change in Enhanced Liver Fibrosis (ELF)